

**DEVELOPMENT OF ^{EZ}DNA DIAGNOSTIC KIT FOR THE
DETECTION OF HOMOZYGOUS DELETION OF *SMN1* GENE IN
SPINAL MUSCULAR ATROPHY (SMA) PATIENTS**

by

MARINI BINTI MARZUKI

**Thesis submitted in fulfilment of the requirements
for the degree of
Master of Science**

FEB 2012

DEDICATIONS

Alhamdulillah to Allah SWT for your bless.

To my beloved and wonderful parents, En. Marzuki Hj Daud and Pn. Sharipah Ab Kadir, who had never stop in supporting and motivating me throughout my study.

To my brothers, Nasri and Fikri, and also my lovely sister, Mardhiah who have given me the energy and courage for my study.

To my dear hubby, Mohd Syafiq who has offered me unconditional love and gave me strength to finish my study.

ACKNOWLEDGEMENTS

I would like to express my deepest gratitude to my supervisor, Assoc. Prof. Dr. Zilfalil b. Alwi, who has been helpful and supportive and also motivated me to become a better student and researcher. His critical comments and valuable insights have guided me in the preparation of this thesis. I am grateful to my co-supervisor; Prof. M. Ravichandran for his guidance and advice especially in the technical parts throughout this study.

To my dear friends and labmates; Sha, K.Chik, K. Finie, Hatin, Ina, Arffah, Mar, Siti, Tasya, Huda, Sathiya, Fatemeh, Yan Yan, Atif, Abg. Nizam, Aizat, Syibli, Amin, Arif, Farah, Loo, Au, and others, I express my deepest appreciation for their encouragements, help and support that have helped me through numerous failed experiments and mental roadblocks. My appreciation also goes out to Human Genome Center lecturers; Assoc. Prof. Dr. Gan, Dr. Teguh, Dr. Sarina, Dr. Badrul and Dr. Wan who have helped me in one way or another during the course of this study.

In addition, I am grateful to the staffs of Department of Medical Microbiology and Parasitology; Dr. Chan, Elina and Balqis, for their kind help and the use of their excellent facilities, as well as the administrative staff and lab technologists from the Cytogenetic Division, Human Genome Center, for their support and motivation throughout my project.

I would like to thank Prof. Hisahide Nishio from the Department of Community Medicine and Social Healthcare Science, Kobe University Graduate School of Medicine,

Kobe Japan for giving me the opportunities to test the diagnostic kit on their Japanese SMA samples. I am also grateful to the USM Short Terms grants that have funded part of this study. On a more personal note, my family has been my strongest motivation and inspiration. No words could ever express my gratitude to them. As a sign of appreciation, I dedicate this thesis to them and hope that I have made them proud.

LIST OF CONTENTS

| CONTENTS | PAGE |
|--|-------------|
| TITLE | i |
| DEDICATION | ii |
| ACKNOWLEDGEMENTS | iii |
| LIST OF CONTENTS | v |
| LIST OF APPENDICES | xi |
| LIST OF TABLES | xii |
| LIST OF FIGURES | xiv |
| LIST OF PLATES | xvi |
| LIST OF ABBREVIATIONS | xvii |
| ABSTRAK | xx |
| ABSTRACT | xxii |
| CHAPTER 1 INTRODUCTION | 1 |
| 1.1 The Overview of Spinal Muscular Atrophy | 1 |
| 1.1.1 Classification of SMA | 2 |
| 1.1.1(a) Type I SMA | 2 |
| 1.1.1(b) Type II SMA | 3 |
| 1.1.1(c) Type III SMA | 3 |
| 1.1.1(d) Type IV SMA | 4 |
| 1.2 SMA as an Autosomal Recessive Disease | 8 |
| 1.3 Diagnosis of SMA | 10 |
| 1.3.1 Clinical Features | 11 |
| 1.3.1(a) Hypotonia | 11 |
| 1.3.1(b) Scoliosis | 11 |

| | | |
|------------------|--|-----------|
| 1.3.1(c) | Tongue Fasciculation | 15 |
| 1.3.2 | Muscle Biopsy | 15 |
| 1.3.3 | Electromyography (EMG) | 17 |
| 1.3.4 | Nerve Conduction Study (NCS) | 17 |
| 1.4 | Molecular Analysis of SMA | 20 |
| 1.4.1 | Survival of motor neuron gene (<i>SMN</i>) | 20 |
| 1.4.2 | The <i>SMN1</i> and <i>SMN2</i> gene | 23 |
| 1.5 | The incidence and deletion frequency of exon 7 of the <i>SMN1</i> gene | 26 |
| 1.6 | Trends in Analysis of the deletion of <i>SMN</i> gene | 27 |
| 1.6.1 | Polymerase Chain Reaction-Restriction Enzyme (PCR-RE) | 27 |
| 1.6.2 | Denaturing High Performance Liquid Chromatography (dHPLC) | 28 |
| 1.6.3 | Quantitative Real-Time PCR | 28 |
| 1.6.4 | Allele specific PCR | 29 |
| 1.7 | Rationale of the rapid screening technique | 30 |
| 1.8 | Lyophilization or freeze-drying process | 33 |
| 1.9 | Aim of the Study | 38 |
| 1.9.1 | General Objective | 38 |
| 1.9.2 | Specific Objectives | 38 |
| CHAPTER 2 | MATERIAL AND METHOD | 39 |
| 2.1 | Study design | 39 |
| 2.1.1 | Flow Chart of the study | 39 |
| 2.2 | Sample Size | 42 |
| 2.3 | Sample collection | 44 |
| 2.3.1 | Review of clinical summary | 44 |
| 2.4 | DNA Extraction | 45 |
| 2.4.1 | Reagents for DNA extraction | 45 |

| | | |
|-------|--|----|
| 2.4.2 | DNA extraction protocol | 45 |
| 2.4.3 | The DNA quality and quantity measurement | 47 |
| | 2.4.3(a) Estimation of DNA concentration by Infinite [®] 200 PRO NanoQuant | 47 |
| | 2.4.3(b) Estimation of DNA quality by electrophoresis | 48 |
| 2.5 | Electrophoresis | 48 |
| | 2.5.1 Preparation of 1X TBE buffer | 48 |
| | 2.5.2 Preparation of agarose gel | 49 |
| | 2.5.3 Preparation of SYBR [®] Green 1 | 49 |
| | 2.5.4 Preparation of 6X loading dye | 50 |
| | 2.5.5 Agarose gel electrophoresis protocol | 50 |
| 2.6 | The detection of homozygous deletion of exon 7 <i>SMN1</i> gene | 51 |
| | 2.6.1 Reagents Polymerase Chain Reaction Restriction Enzyme (PCR-RE) | 51 |
| | 2.6.2 Detection of homozygous deletion of exon 7 <i>SMN1</i> gene using PCR-RE | 51 |
| | 2.6.3 Reagents for Allele Specific Polymerase Chain Reaction (AS-PCR) | 58 |
| | 2.6.4 Multiplex AS-PCR assay | 58 |
| | 2.6.5 Detection of homozygous deletion of exon 7 <i>SMN1</i> gene using AS-PCR | 58 |
| 2.7 | Confirmation of the specific primer | 63 |
| | 2.7.1 DNA sequencing analysis | 63 |
| | 2.7.1(a) Reagents for PCR product purification | 63 |
| | 2.7.1(b) PCR product purification protocol | 63 |
| | 2.7.1(c) Reagents for cycle sequencing | 64 |
| | 2.7.1(d) Cycle sequencing protocol | 65 |
| | 2.7.1(e) Reagents for DNA precipitation | 65 |
| | 2.7.1(f) DNA precipitation protocol | 66 |
| | 2.7.2 Reagents of LightCycler [®] Real-time PCR | 69 |
| | 2.7.2(a) LightCycler [®] Real-time PCR protocol | 69 |
| 2.8 | Comparison of PCR-RE method and AS-PCR method | 73 |
| | 2.8.1 Time and cost efficiency | 73 |
| | 2.8.2 Determination of analytical sensitivity and specificity of the AS-PCR assay | 73 |

| | | |
|------------------|--|-----------|
| | 2.8.2 (a) Analytical sensitivity | 73 |
| | 2.8.2(b) Analytical specificity | 74 |
| 2.9 | Thermostabilization of AS-PCR assay | 74 |
| | 2.9.1 Reagents for deglycerolization of <i>Taq</i> DNA polymerase | 74 |
| | 2.9.2 Deglycerolization of <i>Taq</i> DNA polymerase protocol | 74 |
| | 2.9.3 Reagents for enzyme stabilizer preparation | 76 |
| | 2.9.4 Preparation of Allele specific PCR mixture with enzyme stabilizer | 76 |
| | 2.9.5 Lyophilization of the AS-PCR assay | 77 |
| | 2.9.6 Reconstitution of the lyophilized mixture for PCR | 78 |
| | 2.9.7 Detection of PCR product by agarose gel electrophoresis | 81 |
| 2.10 | Evaluation of the thermostabilized AS-PCR assay | 81 |
| | 2.10.1 Analytical sensitivity | 81 |
| | 2.10.2 Analytical specificity | 81 |
| | 2.10.3 Accelerated stability | 82 |
| 2.11 | Diagnostic evaluation of the thermostabilized AS-PCR assay | 82 |
| CHAPTER 3 | RESULTS | 83 |
| 3.1 | Patients' samples | 83 |
| 3.2 | Categorization of the patients' samples | 87 |
| | 3.2.1 Clinically SMA | 87 |
| | 3.2.2 Clinically not SMA | 88 |
| 3.3 | The genomic DNA quality and quantity measurement | 91 |
| | 3.3.1 Estimation of DNA concentration by Infinite [®] 200 PRO NanoQuant | 91 |
| | 3.3.2 Estimation of DNA quality by agarose gel electrophoresis | 91 |
| 3.4 | Polymerase Chain Reaction Restriction Enzyme (PCR-RE) method | 94 |
| | 3.4.1 Detection of homozygous deletion of exon 7 <i>SMNI</i> gene by PCR-RE | 94 |
| 3.5 | Allele Specific Polymerase Chain Reaction (AS-PCR method) | 99 |
| | 3.5.1 Multiplex AS-PCR Assay | 99 |

| | | |
|------------------|---|------------|
| 3.5.2 | Detection of homozygous deletion of exon 7 <i>SMN1</i> gene by AS-PCR | 102 |
| 3.6 | Confirmation of the specific primers | 104 |
| 3.6.1 | DNA sequencing analysis | 104 |
| 3.6.2 | LightCycler [®] Real-time PCR | 104 |
| 3.7 | Comparison between PCR-RE and AS-PCR method | 109 |
| 3.7.1 | Time efficiency and cost effectiveness | 109 |
| 3.7.2 | Analytical sensitivity | 109 |
| 3.7.3 | Analytical specificity | 110 |
| 3.8 | Thermostabilization of AS-PCR assay | 116 |
| 3.8.1 | Optimization of the thermostabilization of multiplex PCR assay | 116 |
| 3.8.2 | Detection of <i>SMN1</i> gene deletion by thermostabilized AS-PCR | 116 |
| 3.8.3 | Analytical sensitivity | 120 |
| 3.8.4 | Analytical specificity | 120 |
| 3.8.5 | Accelerated stability | 120 |
| 3.9 | Diagnostic evaluation of the thermostabilized AS-PCR | 128 |
| CHAPTER 4 | DISCUSSION | 132 |
| 4.1 | The diagnosis of SMA | 132 |
| 4.2 | The frequency of the deletion of <i>SMN1</i> gene in SMA patients | 133 |
| 4.3 | The limitation of the conventional method | 136 |
| 4.4 | Rapid diagnosis of SMA | 137 |
| 4.5 | The rationale of the AS-PCR in the diagnosis of SMA | 140 |
| 4.6 | Thermostabilization technique as a rapid and effective diagnosis for SMA | 147 |
| 4.7 | Improvement in patient care and management | 150 |
| 4.8 | Future investigations | 151 |
| CHAPTER 5 | CONCLUSION | 152 |

| | |
|---|------------|
| REFERENCES | 154 |
| APPENDICES | 163 |
| LIST OF PUBLICATIONS AND PRESENTATIONS | 181 |

LIST OF APPENDICES

| | PAGE |
|--|-------------|
| Appendix A Ethical Approval | 164 |
| Appendix B Information and Consent form for patients | 165 |
| Appendix C Clinical summary form for SMA | 170 |
| Appendix D List of patients involved in PCR-RE, AS-PCR and thermostabilize AS-PCR | 174 |
| Appendix E List of patients involved in diagnostic evaluation of the thermostabilize AS-PCR on Japanese SMA patients | 178 |

LIST OF TABLES

| | | PAGE |
|-------------------|--|------|
| Table 1.1 | Classification of Spinal Muscular Atrophy based International SMA Consortium Meeting (26th to 28th June 1992) in Bonn, Germany (Munsat <i>et al.</i> , 1992). | 5 |
| Table 2.1 | The sample size calculation of sensitivity and specificity (Lin Naing, 2004) | 43 |
| Table 2.2 | Primer sequence and expected product size for exon 7 <i>SMNI</i> gene and restriction enzyme cutting site for <i>DraI</i> enzyme (van der Steege <i>et. al.</i> , 1995). | 53 |
| Table 2.3 | PCR reagents and the optimum concentration for the detection of homozygous deletion of exon 7 <i>SMNI</i> gene using PCR-RE method. | 54 |
| Table 2.4 | PCR condition for the amplification of exon 7 <i>SMNI</i> gene. | 55 |
| Table 2.5 | Restriction enzyme optimum concentration for the digestion of exon 7 <i>SMNI</i> gene. | 56 |
| Table 2.6 | Primer sequence and expected product size for exon 7 <i>SMNI</i> gene (Feldkötter <i>et al.</i> , 2002) and β -globin gene. | 60 |
| Table 2.7 | PCR reagents and the optimum concentration for the detection of homozygous deletion of exon 7 <i>SMNI</i> gene using multiplex allele specific. | 61 |
| Table 2.8 | PCR condition for the amplification of multiplex allele specific of exon 7 <i>SMNI</i> gene. | 62 |
| Table 2.9 | Reagents needed in cycle sequencing. | 67 |
| Table 2.10 | The PCR condition for the cycle sequencing procedure. | 68 |
| Table 2.11 | The reagents needed in the LightCycler [®] Real-time PCR technique for exon 7 <i>SMNI</i> and β -globin gene. | 71 |
| Table 2.12 | The amplification program for the deletion analysis of exon 7 <i>SMNI</i> gene deletion by LightCycler [®] Real-time PCR technique | 72 |

| | | |
|-------------------|--|-----|
| Table 2.13 | The component needed in the thermostabilized PCR. | 79 |
| Table 2.14 | The PCR condition after deglycerolization of <i>Taq</i> DNA polymerase. | 80 |
| Table 3.1 | This table shows the summary of clinical features of the clinically SMA and clinically not SMA patients. | 90 |
| Table 3.2 | This table shows the concentration and the purity of the genomic DNA after the DNA extraction procedure using the Infinite [®] 200 PRO NanoQuant. | 92 |
| Table 3.3 | This table shows the comparison of time-efficiency and cost-effectiveness between PCR-RE and Allele-specific PCR in SMA genetic diagnosis | 111 |
| Table 3.4 | This table shows the sensitivity and specificity calculation for PCR-RE and AS-PCR method | 112 |
| Table 3.5 | This table shows the analytical specificity of multiplex AS-PCR in the amplification of the target genes compared to PCR-RE method. | 115 |
| Table 3.6 | This table shows the sensitivity and specificity calculation for PCR-RE and thermostabilized AS-PCR | 119 |
| Table 3.7 | This table shows the analytical specificity of thermostabilized AS-PCR in the amplification of the target genes compared to PCR-RE and AS-PCR method. | 124 |
| Table 3.8 | This table shows the accelerated stability of thermostabilized AS-PCR in the amplification of the target genes in different temperature. | 125 |
| Table 3.9 | This table shows the accelerated stability calculation (Zheng <i>et al.</i> , 2005). | 127 |
| Table 3.10 | This table shows the sensitivity and specificity calculation for PCR-RE and thermostabilized AS-PCR | 130 |
| Table 3.11 | This table shows the analytical specificity of diagnostic kit (tested in Japan) in the amplification of the target genes compared to PCR-RE method. | 131 |
| Table 4.1 | The summary of previous study on diagnosis of SMA using allele specific PCR | 145 |

LIST OF FIGURES

| | | PAGE |
|--------------------|--|------|
| Figure 1.1 | A malay boy with Type II SMA (Adapted from Watihayati <i>et al.</i> , 2007). This patient passed away in February 2010. | 6 |
| Figure 1.2 | A malay girl with Type III SMA (Adapted from Watihayati <i>et al.</i> , 2007). This patient is still undergoing treatment at Hospital USM. | 7 |
| Figure 1.3 | This figure shows an autosomal recessive inheritance pattern in Spinal Muscular Atrophy. | 9 |
| Figure 1.4 | The figure shows an SMA patient with hypotonia. | 13 |
| Figure 1.5 | These figures show SMA patient spine who suffered from scoliosis. Figure A shows the actual patient spine and Figure B shows the cob angle for the measurement of levoscoliosis. | 14 |
| Figure 1.6 | The figure shows the procedure for muscle biopsy | 16 |
| Figure 1.7 | The figure shows example of the procedures for Electromyography (EMG) | 19 |
| Figure 1.8 | The figure shows example of the procedures for Nerve Conduction Study (NCS) | 19 |
| Figure 1.9 | This figure shows the location of the human chromosome 5 and the location of the <i>SMN</i> gene in the chromosome. | 22 |
| Figure 1.10 | This diagram shows (A) the inverted duplication of <i>SMN1</i> and <i>SMN2</i> gene and (B) the nucleotide differences between both genes. | 25 |
| Figure 1.11 | The work flow summary of the development of a thermostabilize product | 32 |
| Figure 1.12 | The summary of the lyophilization process | 36 |
| Figure 1.13 | The diagram shows the sublimation process of freeze-drying. | 37 |
| Figure 2.1 | Flow chart of the study. | 41 |

| | | |
|-------------------|--|-----|
| Figure 2.2 | The diagram showing the cutting site of the restriction enzyme to exon 7 <i>SMN1</i> gene. This cutting site will differentiate the <i>SMN1</i> and <i>SMN2</i> gene respectively. | 57 |
| Figure 3.1 | This figure shows the referred SMA cases to Human Genome Center, USM from 2003 to 2010. | 85 |
| Figure 3.2 | This diagram shows the total number of patients who fulfilled the criteria of SMA and those who did not fulfilled the criteria of SMA. | 86 |
| Figure 3.3 | This figure shows the distribution of type of SMA based on the clinical features and age of onset in clinically SMA patients. | 89 |
| Figure 3.4 | This diagram shows the distribution of the deletion, non deletion of <i>SMN1</i> gene and deletion of <i>SMN2</i> gene samples in clinically and clinically not SMA patients | 98 |
| Figure 3.5 | This figure shows the electropherogram of DNA sequencing analysis. The arrow showed the exact location of the specific nucleotide in exon 7 <i>SMN1</i> gene (c.840C) | 105 |
| Figure 3.6 | This figure shows the melting curve analysis of exon 7 <i>SMN1</i> gene showed that the products melted completely at the 78°C. | 106 |
| Figure 3.7 | This figure shows the standard curves of amplification of exon 7 <i>SMN1</i> gene by LightCycler® Real-time PCR | 107 |
| Figure 3.8 | This figure shows the melting curves analysis of different concentration of DNA template in deleted and non deleted samples. | 108 |
| Figure 4.1 | The primers used in the present study as compared to those used in other previous studies. | 146 |

LIST OF PLATES

| | | PAGE |
|-------------------|---|-------------|
| Plate 3.1 | The measurement of the quality of genomic DNA by electrophoresis | 93 |
| Plate 3.2 | This gel electrophoresis shows the amplification of PCR product of exon 7 <i>SMNI</i> gene. (A) and (B) indicate the samples of the SMA cases. | 96 |
| Plate 3.3 | This gel electrophoresis gel shows the detection of homozygous deletion of exon 7 <i>SMNI</i> gene by PCR-RE | 97 |
| Plate 3.4 | This gel electrophoresis shows the optimization of annealing temperature of multiplex AS-PCR | 100 |
| Plate 3.5 | This gel electrophoresis shows the optimization of primers concentration of multiplex AS-PCR | 101 |
| Plate 3.6 | This gel electrophoresis shows the detection of homozygous deletion of exon 7 <i>SMNI</i> gene by AS-PCR | 103 |
| Plate 3.7 | This gel electrophoresis shows the analytical sensitivity of multiplex AS-PCR | 113 |
| Plate 3.8 | This gel electrophoresis shows the analytical specificity of multiplex AS-PCR | 114 |
| Plate 3.9 | This gel electrophoresis shows the optimization of <i>Taq</i> DNA polymerase in thermostabilized AS-PCR. | 117 |
| Plate 3.10 | This gel electrophoresis shows the similarity of the PCR-RE results (gold standard) (A) with the thermostabilized diagnostic kit (B) . The gel electrophoresis was done immediately after the thermostabilized process. | 118 |
| Plate 3.11 | This gel electrophoresis shows the analytical sensitivity (limit of detection) of the thermostablized diagnostic kit. | 122 |
| Plate 3.12 | This gel electrophoresis shows the amplification of the target genes by thermostabilized AS-PCR. A, B and C indicated the 1 st , 2 nd and 3 rd agarose | 123 |

gel electrophoresis.

- Plate 3.13** This gel electrophoresis shows the stability of the thermostabilized kit at 27°C. **A** indicated the storage on the 7th day; **B** indicated the storage on the 30th; **C** indicated the storage on the 60th day. 126
- Plate 3.14** The gel electrophoresis shows the amplification of diagnostic thermostabilized AS-PCR in Japan. **A, B and C** indicated the amplification of various Japanese SMA samples. 129

LIST OF ABBREVIATIONS

| | | |
|------------------------------------|---|---|
| % | : | percentage |
| °C | : | degree celcius |
| µl | : | microliter |
| A ₂₆₀ /A ₂₈₀ | : | ratio absorbance of genomic DNA |
| AE buffer | : | elution buffer |
| AS-PCR | : | allele specific polymerase chain reaction |
| BL buffer | : | lysis buffer |
| bp | : | base pair |
| BSA | : | bovine serum albumin |
| BW buffer | : | washing buffer I |
| CBs | : | cajal bodies |
| ddH ₂ O | : | deionized distilled water |
| dHPLC | : | denaturing high performance liquid chromatography |
| DNA | : | deoxyribonucleic acid |
| dNTP | : | dinucleotide triphosphatase |
| EMG | : | electromyography |
| Gems | : | Gemini of cajal bodies |
| kb | : | kilo base |
| kDa | : | kilo dalton |
| MgCl ₂ | : | magnesium chloride |
| min | : | minute |
| ml | : | mililiter |
| mM | : | milimolar |
| NCS | : | nerve conduction study |
| ng/µl | : | nano gram per microliter |
| PCR | : | polymerase chain reaction |
| PCR-RE | : | polymerase chain reaction restriction enzyme |
| pmol | : | pico mole |
| pre-mRNA | : | precursor messenger ribonucleic acid |

| | | |
|---------------------------|---|---|
| RNA | : | ribonucleic acid |
| rpm | : | round per minute |
| SMA | : | spinal muscular atrophy |
| SMN | : | survival of motor neuron |
| SMN1 | : | survival of motor neuron 1 |
| SMN2 | : | survival of motor neuron 2 |
| snRNPs | : | small nuclear ribonucleoprotein |
| SYBR [®] Green I | : | SYBR [®] Green I nucleic acid staining |
| <i>Taq</i> | : | <i>thermophilus aquaticus</i> |
| TW buffer | : | washing buffer II |
| U | : | unit |
| UV | : | ultraviolet |
| V | : | volt |

**PEMBANGUNAN KIT ^{EZ} DNA DIAGNOSTIK UNTUK PENGESANAN
KEHILANGAN HOMOZIGUS GEN *SMN1* PADA PESAKIT ATROPI OTOT
SPINA (SMA)**

ABSTRAK

Spinal Muscular Atrophy (SMA) adalah penyakit yang mempunyai frekuensi yang kedua tertinggi yang menyebabkan kematian dikalangan kanak-kanak. Kadar kejadian penyakit ini adalah didalam anggaran 1 setiap 10000 kelahiran. SMA digambarkan melalui kelemahan otot secara beransur-ansur akibat daripada kemerosotan dan kehilangan neuron motor didalam bahagian hadapan tulang belakang. *Survival of Motor Neuron (SMN)* merupakan gen yang bertanggungjawab terhadap penyakit SMA. Gen *SMN1* dan *SMN2* berkongsi lebih dari 99.8% jujukan yang sama dan ia hanya boleh dibezakan dengan perubahan bes pada exon 7 dan 8. Gen *SMN1* tidak dapat dikesan pada kebanyakan kes SMA disebabkan oleh kehilangan atau penukaran bes tersebut. Kebiasaanya, kehilangan gen *SMN1* dapat dikesan menggunakan kaedah Reaksi Rantai Polimer-Enzim Pembatasan (PCR-RE). Kaedah ini memerlukan masa yang lama, kos yang tinggi dan memerlukan pencernaan enzim pembatasan yang memerlukan banyak jumlah DNA yang diamplifikasi dimana ia akan muncul selepas pencernaan dan berkemungkinan menunjukkan keputusan yang salah. Untuk mengatasi masalah tersebut, kaedah alternatif menggunakan primer alel-spesifik khusus untuk diagnosis molekul SMA lebih menjimatkan masa dan kos. Platform 'freeze-dry' telah digunakan pada multiplex Reaksi Rantai Polimer-Alel Spesifik (AS-PCR) untuk pembangunan kit yang stabil suhu. Sejumlah satu ratus empat puluh tiga (143) sampel daripada pesakit yang disyaki menghidapi SMA telah digunakan di dalam kajian ini. Kaedah diagnosis molekul menggunakan PCR-RE telah dilakukan untuk mengesan kehilangan dan

kehadiran gen *SMNI* didalam semua sampel tersebut. Lima puluh enam sampel telah dikesan mempunyai kehilangan gen *SMNI*, sementara 87 sampel lagi telah dikesan tidak mengalami kehilangan gen tersebut. DNA telah diekstrak menggunakan kit komersil yang sedia ada. Untuk menilai keberkesanan kaedah AS-PCR, kesemua 143 sampel telah dianalisa semula menggunakan kaedah AS-PCR. Untuk mengesan amplifikasi PCR dan mengelakkan keputusan yang salah, gene 'housekeeping' (*β -globin gene*) telah digunakan sebagai kontrol dalaman. Keputusan daripada kedua-dua kaedah kemudiannya telah di bandingkan dan dinilai dari segi masa kajian dan kos setiap sampel. Kemudian, analisis kesensitiviti, ketepatan dan kestabilan untuk kit stabil suhu AS-PCR telah diperhatikan dan dinilai. Seterusnya, kit stabil suhu AS-PCR telah dianalisis keatas sampel SMA Jepun. Kajian ini telah menunjukkan 100% keputusan yang sama diantara kaedah PCR-RE dan AS-PCR. Sementara, kit stabil suhu AS-PCR juga menunjukkan 100% ketepatan dan kesensitifan diantara kaedah PCR-RE dan AS-PCR biasa. Berdasarkan ujian kestabilan kit stabil suhu AS-PCR menunjukkan sekurang-kurangnya 2.5 tahun kestabilan pada suhu dibawah 4°C. Keputusan kajian menunjukkan kit stabil suhu AS-PCR adalah berkesan standing teknik PCR-RE untuk pengesanan kehilangan gen *SMNI*. Seterusnya, penilaian diagnostik keatas populasi Jepun menunjukkan ketepatan kit ini adalah 98% sementara kesensitifannya tetap pada 100%. Kesimpulannya, pengecualian pencernaan enzim telah menjadikan kaedah AS-PCR lebih murah dan pantas berbanding kaedah lama. Ia dapat mengurangkan lima kali ganda masa dan menjimatkan 69% kos setiap sampel. Kit stabil suhu AS-PCR juga menunjukkan keberkesanan dan juga kelebihan berbanding kaedah PCR-RE didalam diagnosis molekul SMA yang mana menunjukkan ia boleh digunapakai di dalam diagnosis rutin SMA.

**DEVELOPMENT OF ^{EZ}DNA DIAGNOSTIC KIT FOR THE DETECTION OF
HOMOZYGOUS DELETION OF *SMN1* GENE IN SPINAL MUSCULAR
ATROPHY (SMA) PATIENTS**

ABSTRACT

Spinal Muscular Atrophy (SMA) is the second most frequent fatal autosomal recessive disorder of childhood. The incidence of this disease is approximately 1 in 10000 live births. SMA is characterized by progressive muscle weakness resulting from degeneration and loss of motor neurons in the anterior horn of spinal cord. The responsible genes for SMA are *Survival of Motor Neuron (SMN)*. *SMN1* and *SMN2* genes share over 99.8% sequence homology and they can be distinguished by base changes in both exons 7 and 8. *SMN1* gene is not detectable in majority of SMA cases due to either deletion or conversion. Conventionally, the homozygous deletion of *SMN1* gene is detected using Polymerase Chain Reaction-Restriction Enzyme (PCR-RE) method. This method is time consuming, expensive and requires restriction enzyme digestion and a considerably high amount of amplified DNA to be visible after digestion. This may lead to false-negative results. To avoid these problems, we have developed an alternative method using an allele-specific primer for the molecular diagnosis of SMA which is more time-saving and cost-effective. The freeze dry platform was applied to the multiplex AS-PCR for the development of a thermostabilize diagnostic kit. A total of one hundred and forty three samples of clinically suspected SMA were included in this study. Conventional molecular diagnosis using PCR-RE was done to detect the presence or absent of *SMN1* deletion in these samples. Fifty-six samples were found to have deletion of the *SMN1*, while the remaining 87 samples were

found to have no deletion of the gene. To evaluate the reliability of the AS-PCR method, all 143 samples were then re-analyzed using AS-PCR. To monitor the PCR amplification and to avoid the false negative results, a housekeeping gene (*β-globin* gene) was used as an internal control. The results from both methods were subsequently compared and evaluated for the experimental duration and per sample cost. The sensitivity, specificity and stability of the thermostabilized AS-PCR were monitored and subsequently analyzed. This thermostabilized AS-PCR was then tested on Japanese SMA samples. Our study showed 100% similarity between those using PCR-RE and AS-PCR. The thermostabilized AS-PCR also showed 100% specificity and sensitivity with PCR-RE and AS-PCR methods. Based on the accelerated stability, the thermostabilized AS-PCR has the minimum of 2.5 years shelf life in temperature below 4°C. Our results suggest that the thermostabilized AS-PCR is a reliable technique when compared to the PCR-RE method in the screening of *SMN1* deletion. Furthermore, the diagnostic evaluation on Japanese population suggested that the specificity of the kit is 98% while the sensitivity remains 100%. In conclusion, the exclusion of digestion step makes AS-PCR method cheaper and faster compared to the conventional method. It can reduce almost five times of the time and 69% of the cost per sample. The thermostabilized AS-PCR also reliable and superior over PCR-RE method in the molecular diagnosis of SMA, suggesting that it could be applied in the routine diagnosis of SMA.

CHAPTER 1

INTRODUCTION

1.1 The Overview of Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA) is the autosomal recessive genetic disease which can lead to infant mortality (Robert *et. al.*, 1970; Pearn 1973, 1978; Czeizel and Hamula, 1989). It is the second most common lethal genetic disease leading to childhood death after cystic fibrosis (Steward *et. al.*, 1998). The incidence of this disease is 1 in 10,000 live births while 1 in 40 normal people carry one copy of this lethal gene (Adreassi *et. al.*, 2001). Markowitz *et al.* (2004) was reported, the early founder of SMA was described by Guido Werdnig and Johann Hoffmann. The main cause for SMA is the degeneration of alpha-motor neurons that leads to the progressive muscle weakness. This alpha-motor neuron was located at the anterior horn of the spinal cord. The degeneration of this neuron could lead to the failure of transmission of the impulse from brain to the muscle neuron. When the impulse did not normally function, the normal function of the muscle will reduce and muscle will slowly shrink and atrophy. Furthermore, most of the SMA patients commonly show the general symptoms such as

muscle atrophy, weakness of cry, poor muscle tone, scoliosis, hypotonia and feeding difficulties (Zerrez *et al.*, 1995). The proximal muscles of SMA patients are mainly weaker than the distal muscle due to the location which was closest to the spinal cord.

1.1.1 Classification of SMA

Spinal Muscular Atrophy is classified based on age of onset and the clinical severity, as described in the International SMA Consortium Meeting (26th to 28th June 1992) in Bonn, Germany (Munsat *et al.*, 1992) (Table 1.1). This guideline was very useful for the determination of the prognosis and management of SMA. However, the clinical symptoms of SMA commonly overlap with other neuromuscular disorders (Chien *et al.*, 2005). Hence, many affected patients died due to the misdiagnosis of the clinical symptoms and lack of awareness among the clinician. In some condition, the molecular genetic analysis is useful for the confirmation of the clinical diagnosis (Chien *et al.*, 1995).

1.1.1(a) Type I SMA

Type I SMA is the severe type of SMA and it is also known as Werdnig-Hoffmann disease or acute SMA. Patient with type I SMA is diagnosed by the early age of onset which started between 0 to 6 months of age. Type I SMA patient usually have a very limited life expectancy (less than 2 years). Most of the patients are not able to sit without support. Generally, patients diagnosed with this form have very little control of their heads and they also cough and cry weakly. They lose the ability to swallow and feed

before they reach 1 year of age. Over time, their trunk and limbs will be weakened and it normally spreads to the intercostals muscles, making an abnormal respiratory cycle. The risk of early mortality is usually associated with bulbar dysfunction and respiratory complications.

1.1.1(b) Type II SMA

An intermediate form of SMA is the type II SMA. Patient with type II SMA is generally diagnosed around 6 to 18 months of age, but it may start earlier. Some of these patients which have been classified to have SMA type II are able to sit up without support while others can remain sitting if they are positioned, but they still cannot sit without any support. In the other case, some of the patients could stand with support and this showed that they have a better muscle development than others. However, this patient is still unable to walk. In type II SMA patient, some of them will experience reducing weight due to the bulbar weakness which combined with the swallowing difficulties. Furthermore, these patients may have problems with coughing and with cleaning secretions from the trachea, and as well as tongue fasciculation and later they can suffer from scoliosis and contractures. Their life expectancy is around 10 to 40 years.

1.1.1(c) Type III SMA

Kugelberg-Welander syndrome is also known as type III SMA or juvenile SMA. The actual age varies but according to the consortium, the age of onset for type III SMA is after 18 months. Wirth *et al.* (2000) divided the type III SMA into two types, which is

type III(a) SMA and type III (b) SMA. Type III(a) SMA is when the disease started before 3 years of age, while if the onset is later, it is called type III(b) SMA. The major difference between both types is the preservation of the ability to walk. Patients with type III(a) are able to walk until they are 20, while type III(b) patients are able to walk for their whole life. The general problems in SMA type III patient are difficulties in swallowing and coughing when feeding. Scoliosis will develop later in their life.

1.1.1(d) Type IV SMA

The adulthood form of SMA is also known as type IV SMA. There is no consensus on the age of onset of type IV SMA. Several cases study have reported that this type of SMA started after 10 years of age (Russman *et al.*, 1995) while another report by Wang *et al.* (2007) stated that their weakness normally emerges during the second or third decade of life, or at about 30 years of age. Normally, the motor function involvement is mild and there are no problems with deglutition or respiration. Type IV SMA patients are able to walk normally and have normal life expectancy.

Table 1.1 Classification of Spinal Muscular Atrophy based on the International SMA Consortium Meeting (26th to 28th June 1992) in Bonn, Germany (Munsat *et al.*, 1992).

| Phenotype | Age of Onset | Life Span | Motor Milestone |
|------------------|---------------------|------------------|------------------------|
| SMA I | Before six months | Reduced | Sit with support only |
| SMA II | 6-18 months | Adolescence | Independent sitting |
| SMA III | After 12 months | Adult | Independent ambulation |
| SMA IV | Adulthood | Normal | Normal |



Figure 1.1 A Malay boy with Type II SMA (Adapted from Watihayati *et al.*, 2007). This patient passed away in February 2010.



Figure 1.2 A Malay girl with Type III SMA (Adapted from Watihayati *et al.*, 2007). This patient is still undergoing treatment at Hospital USM.

1.2 SMA as an Autosomal Recessive Disease

Spinal Muscular Atrophy is one of the autosomal recessive diseases inheritance pattern, leading to the early death in children. In autosomal recessive disease, two copies of the gene must be mutated for a person to be affected. In most of the SMA cases, patient usually has unaffected parents but they carry a single copy of the mutated gene while the other gene is normal. They are called a carrier. When a carrier marries another carrier, they will have a 25% chance with each pregnancy of having an affected child.

As an example in Figure 1.3, 'A' is the normal gene and 'a' is the mutated gene. When both the parents have an 'Aa' gene which mean they are a carrier, they will have 25% chance to get a normal homozygous 'AA' child, 50% chance a carrier 'Aa' heterozygous child and 25% an affected child (aa) which carry both mutated genes from the parents (Figure 1.3).




Figure 1.3 This figure shows an autosomal recessive inheritance pattern in Spinal Muscular Atrophy.

1.3 Diagnosis of SMA

In order to diagnose patients with SMA, the general symptoms of SMA need to be clinically present. Since SMA is caused by the progressively degeneration of the alpha-motor neuron, the affected neuron is only the motor neuron, not the sensory neuron. SMA patients therefore commonly present with weakness and atrophy of the voluntary muscle of the legs, arms and trunk. Most of the SMA cases could be identified with the molecular genetic testing of *SMN1* gene while in some cases, the clinical diagnosis are essential for the confirmation of SMA due to the heterozygous deletion or other mutations in the *SMN1* gene (Hahnen *et al.*, 1995; Rodrigues *et al.*, 1995). In addition, due to the low prevalence of SMA, the diagnosis of SMA becomes quite challenging. There are numbers of neurogenetic diseases that could present with similar symptoms of SMA. Hence, diagnosis of clinical presentation of SMA should be investigated with care (Araújo *et al.*, 2005) since these clinical signs can also be observed in other neuropathologies (Baioni *et al.*, 2010). Generally, SMA patients manifest clinical characteristic signs such as hypotonia, tongue fasciculation and scoliosis.

1.3.1 Clinical Features

1.3.1(a) Hypotonia

One of the clinical features of SMA is hypotonia. Hypotonia is a symptom where the muscle state is very low, which is caused by the defect of the motor nerve control by the brain. Most of the SMA cases which was detected in the infant state, the patient will have ‘floppy infant syndrome’ which is described an abnormal limpness when an infant is put in prone position. They easily slip through one’s hand as showed in figure 1.4. The patient usually could not control the movement of their head and have difficulties in feeding. Usually, this patient is classified in the type I SMA and died before 6 months of age.

1.3.1(b) Scoliosis

Scoliosis is a condition which a person’s spine is curved from side to side. The spine will form as an ‘S’ rather than a straight line (Figure 1.5). It is classified as either congenital (vertebral anomalies present at birth), idiopathic (unknown cause) or neuromuscular. The severe cases of scoliosis can lead to diminishing lung capacity, which put pressure on the heart and restricting physical activities. Patient with scoliosis is examined by physical examination involving the skin to indicate neurofibromatosis, the feet for cavovarus deformity, abnormal reflexes and muscle tone spacity. Generally there is no medical treatment for scoliosis because of its complexity. Patient who suffers from scoliosis usually will have a physical therapy, using a brace to support the body

and surgery to increase their self care activities and to prevent the scoliosis to become worsen.



Figure 1.4 The figure shows the SMA patient with hypotonia. (Adapted from <http://www.nlm.nih.gov/medlineplus/ency/images/ency/fullsize/17229.jpg>)




Figure 1.5 This figures show SMA patient spine who suffered from scoliosis. Figure **A** shows the actual patient spine (Adapted from <http://www.nlm.nih.gov/medlineplus/ency/imagepages/1114.htm>) and Figure **B** shows the cob angle for the measurement of levoscoliosis (Adapted from http://en.wikipedia.org/wiki/File:Scoliosis_cobb.gif)

1.3.1(c) Tongue Fasciculation

Tongue fasciculation is an abnormal pattern of non rhythmic, unorganized, contraction of individual muscle fibres across the surface of the tongue. The involuntary contraction of the muscle fibres are generally innervated by a motor unit. The fasciculation can often be visualised and take the form of a muscle twitch or dumpling under the skin, but usually do not generate sufficient force to move a limb. The tongue fasciculation may represent a condition such as in SMA.

1.3.2 Muscle Biopsy

A muscle biopsy is a procedure to remove a piece of muscle tissue from the respective target muscle. The procedure of muscle biopsy is involving a small surgical incision using a biopsy needle (figure 1.6). A muscle biopsy is generally used in the determination of a muscle and nerve problem such as nerve system, connective tissue, vascular system or musculoskeletal system (Araújo *et al.*, 2005; Wirth *et al.*, 2006). In SMA patient, a muscle biopsy can help the clinician to distinguish the myopathies (pathology is in the muscle tissue) and neuropathies (pathology is at the nerves innervating the muscle). In some cases, muscle biopsy is unnecessary but in other cases, it can help to clarify the muscle type and get a clear picture of which type of muscle dominates their body (Pons *et al.*, 1996).



Figure 1.6 The figure shows the procedure for muscle biopsy (Adapted from <http://www.hes.cahs.colostate.edu.html>)

1.3.3 Electromyography (EMG)

Electromyography (EMG) is a technique to evaluate and record the electrical activity produced by the skeletal muscle. EMG is performed by an electromyograph and the signal which is produced is called an electromyogram (figure 1.7). Electromyograph will detect the electrical potential that is generated by muscle cells when these cells are electrically or neurologically activated (Reed, 2002).

The muscle abnormalities, activation level, recruitment order and biomechanics of human movement can be analyzed by EMG. Normal muscle tissue is electrically inactive while in the resting condition while in the neurophatic disease, the action potential amplitude and duration is twice the normal because of the increased number of fibres per motor unit because of the innervations of denervated fibres (Araújo *et al.*, 2005; Wirth *et al.*, 2006). In contrast, the myophatic disease shows the action potential amplitude and duration is decreased than the normal level.

1.3.4 Nerve Conduction Study (NCS)

Nerve Conduction Study (NCS) is the procedure to evaluate the function and the ability of electrical conduction of the normal and sensory nerve of the human body (figure 1.8). In NCS test, the Nerve Conduction Velocity (NCV) measurement was made to set the actual mean of the test but in certain cases, this measurement may be misleading because it is the only one measurement in the test suite.

The NCS consist of four components which are motor NCS, sensory NCS, F-wave study and H-reflex study. All of these components were done to stimulate and record the wave and reflex of the motor nerves and muscle potential. The interpretation of NCS is complex, but generally the abnormality in motor nerves is indicated by the slowing of the NCV wave (Araújo *et al.*, 2005; Wirth *et al.*, 2006). This test is not invasive, but can be painful due to the electrical shock associated with the low electrical current.




Figure 1.7 The figure shows the example of the procedures for Electromyography (EMG) (Adapted from <http://cdn.nursingcrib.com/wp-content/uploads/emg.jpg>)




Figure 1.8 The figure shows the example of the procedures for Nerve Conduction Study (NCS) (Adapted from <http://www.drbezner.com/ncs.jpg>)

1.4 Molecular Analysis of SMA

1.4.1 Survival of motor neuron gene (*SMN*)

Almost sixteen years back, the inverted duplication of a 500kb element in a long arm of a normal chromosome 5 (5q13) have been discovered by Lefebvre *et al.* (1995) which contains the gene for type I SMA patient (figure 1.9). They found a 20kb gene which encode 294 amino acid protein within the telomeric portion that known as survival of motor neuron gene (*SMN* gene). This gene is also known as telomeric *SMN* gene (*SMNT*) (Lefebvre *et al.*, 1995). *SMN* gene is a component of a large highly stable protein complex that can be found in both cytoplasmic and nuclear compartments (Liu *et al.*, 1997; Lefebvre *et al.*, 1997; Meister *et al.*, 2000). The human *SMN* gene was reported to have 8 exons (Lefebvre *et al.*, 1995). However, Burglen *et al.* (1996) have characterized the *SMN* gene and showed that it has 9 exons because exon 2 is divided into two exons; exon 2a and 2b. The *SMN* gene stop codon was found in the exon 7 while the exon 8 is not translated.

The *SMN* protein is found throughout the body but in higher level in the spinal cord (Coovert *et al.*, 1997). The function of *SMN* protein in the spinal cord is in the maintenance of the nerve cells that is called motor neurons. Healthy motor neurons are critical because they will control the movement of the muscle. In cells, the *SMN* protein is found in a sub nuclear form known as Gemini of Cajal bodies (Gems) because of its similarities in number and size with Cajal bodies (CBs) (Liu and Dreyfuss, 1996). The Gems also have the same response and metabolic condition as CBs. However, the

presence of small nuclear ribonucleoprotein (snRNPs) in CBs has made it different from Gems. The snRNPs is a complex of snRNP which is consisted of U1, U2, U4/U6 and U5 and it plays an important role in assembling the cellular machinery in the processing molecules which is called pre-messenger RNA (pre-mRNA) (Liu and Dreyfuss, 1996). The full length of *SMN* protein is needed for the interaction of this protein with other protein to form a large complex of multiprotein.

The *SMN* protein, also has an additional function in nerve cells that is important for dendrites and axons which are important for the transmission of impulses from nerve to nerve and from nerves to muscles (Fan and Simard, 2002).

In the fetus period, the *SMN* gene is normally inactive and allows normal apoptosis in the developing fetus (Soler-Botija *et al.*, 2002). This gene becomes active in the healthy mature fetus to stabilize the neuronal population. In its absence, programmed cell death persists. The mechanism and timing of abnormal motor neuron death remain unknown (Brzustowicz *et al.*, 1990; Pern *et al.*, 1978).




Figure 1.9 This figure shows the location of the human chromosome 5 and the location of the *SMN* gene in the chromosome. (Adapted from <http://www.ensembl.co.uk/>)

1.4.2 The *SMN1* and *SMN2* gene

A study by Coover *et al.* (1997), found that the *SMN* protein is expressed from both *SMN1* and *SMN2* genes. However, the exon 7 *SMN1* gene is not detectable in 95% of SMA cases due either deletion or conversion of the sequences (Lefebvre *et al.*, 1995). The other 5% of non deleted SMA patients is believed to have intragenic mutations; missense mutation, frameshift mutation, nonsense mutation, Alu-mediated deletion and donor splice site mutation (Wirth *et al.*, 1999). The study by Coover *et al.* (1997) also demonstrated that the *SMN2* gene was found in more than 95% of the controls at the duplicated centromeric region of the chromosome 5 (Coover *et al.*, 1997), hence there is no report about the patients who absent both of these genes.

Both of these genes share over 99.8% of the similar nucleotide and are different in only five nucleotides. *SMN1* and *SMN2* can be distinguished by only 5 nucleotide differences located in one in intron 6 (G>A), one in exon 7 (C>T), two in intron 7 (A>G; A>G) and one in exon 8 (G>A)(Figure 1.10).

SMN1 and *SMN2* expressed the same peptide sequence for the *SMN* gene. However, because of one nucleotide difference in exon 7 (C>T) between *SMN1* and *SMN2* gene, the alteration of one nucleotide in exon 7 *SMN2* gene will cause the splicing of exon 7 during the transcriptional process, and later produce a truncated *SMN2* protein (Lorson *et al.*, 1999). This truncated *SMN2* gene is not stable *in vivo* and *in vitro* and it also could not self-oligomerized (Hofmann *et al.*, 2000).

Rochette *et al.* (2001) reported that *SMN2* is unique in man since the chimpanzee has only multiple copy of *SMN1* gene. The *SMN1* gene is not present in most of SMA patients; however they retain at least one copy of *SMN2*. (Figure 1.10)

However, in 10% of the cases, the *SMN2* may also produce full length *SMN* protein (Lefebvre *et al.*, 1995). The severity of the disease depends on the efficiency of splicing of this *SMN2* in order to produce the full length *SMN* protein. The low level of *SMN* could still allow the development of the embryo but the survival of motor neuron sufficiency was still abnormal.




Figure 1.10 This diagram shows (A) the inverted duplication of *SMN1* and *SMN2* gene and (B) the nucleotide differences between both genes.